Singapore's research community has long been at the forefront of tackling antimicrobial resistance (AMR), a global crisis threatening millions of lives annually. In a groundbreaking study published in early 2026, scientists from Nanyang Technological University (NTU) and collaborators have illuminated a critical evasion tactic employed by the notorious pathogen Mycobacterium abscessus. This non-tuberculous mycobacterium, known for its resilience against conventional antibiotics, switches from a 'smooth' to a 'rough' morphotype when targeted by bacteriophages—viruses that selectively destroy bacteria. This discovery not only unravels the mechanism behind phage resistance but also proposes practical solutions like dual-phage cocktails to restore treatment efficacy.

The findings, detailed in the Proceedings of the National Academy of Sciences (PNAS), emerge from meticulous experiments blending genomic sequencing, in vitro assays, and animal models. Led by postdoctoral researcher Jun Hao Liew at NTU's Lee Kong Chian School of Medicine (LKCMedicine), in collaboration with A*STAR's Infectious Diseases Labs and the National University of Singapore (NUS), the work addresses a gap in phage therapy applications. Previously, efforts focused predominantly on the rough variant, overlooking the smooth form prevalent in Asian clinical isolates—up to 54% in the study's cohort of 197 strains.

Understanding Mycobacterium abscessus: The Smooth vs. Rough Dilemma

Mycobacterium abscessus belongs to the Mycobacterium genus, infamous for species like M. tuberculosis, the tuberculosis causative agent. Unlike TB, M. abscessus primarily afflicts immunocompromised individuals, cystic fibrosis patients, and those with chronic lung conditions, leading to severe, persistent infections. Its intrinsic multidrug resistance stems from a thick, waxy cell wall rich in mycolic acids, rendering many antibiotics ineffective. Treatment regimens often span 12-18 months, with success rates below 50%.

Bacteria exhibit two morphotypes: smooth (S), producing glycopeptidolipids (GPL) that form a protective outer layer aiding biofilm formation and immune evasion; and rough (R), GPL-deficient, more virulent in clinical settings but sometimes more phage-susceptible. In Asia, smooth strains dominate environmental and early infection samples, complicating therapy as they switch under pressure. The NTU team quantified this: in lab cultures, phage exposure triggered 4-28% switching rates, confirmed via thin-layer chromatography (TLC) showing GPL loss and whole-genome sequencing revealing mutations in the GPL locus (e.g., mps1, mmpL4).

Decoding Phage Therapy: A Precision Weapon Against Superbugs

Bacteriophage therapy harnesses viruses that infect and lyse specific bacteria without harming human cells. Discovered over a century ago, phages fell out of favor with antibiotics' rise but are resurging amid AMR. In Singapore, a hub for biotech innovation, institutions like NTU and A*STAR have pioneered phage engineering for pathogens like Acinetobacter baumannii and now mycobacteria. Phages bind bacterial receptors, inject DNA, replicate, and burst the host—highly targeted, self-amplifying, and low-toxicity.

Challenges include bacterial resistance via receptor mutation, CRISPR defense, or morphotype shifts. The NTU study used ΦJabs (Siphophage targeting smooth via GPL-linked receptors) and ΦJun14 (myophage for rough). Adsorption assays showed ΦJabs fails on rough due to absent GPL, explaining evasion. Complementation experiments restored susceptibility, proving causality.

• Phage adsorption: 90% efficient on smooth, <10% on rough.
• Mutation hotspots: Frameshifts in 70% of resistant mutants.
• Lysogeny risk: 2-6% of survivors integrate phage DNA, potentially arming bacteria.

The NTU Study: From Lab to Living Models

Liew's team isolated phage-resistant mutants (PRMs) from smooth clinical strain CIP_S post-ΦJabs exposure. Sequencing 50+ PRMs identified recurrent GPL disruptions. In zebrafish embryos (transparent infection model), phage-treated fish yielded rough PRMs at 28.5%, mirroring mutations. Mouse lungs post-intranasal challenge showed 4.2% switching, with reduced bacterial load but emergent resistance—real-world proof.

Cryo-EM visualized phages: tailed viruses with ~150 nm heads. Infectivity profiles on 197 Asian isolates revealed 80% rough susceptibility to ΦJun14, but smooth dominance (54%) necessitates cocktails. Dual-phage (ΦJabs + ΦJun14) reduced CFUs 1000-fold over singles at 120 hours, preventing escape.Read the full PNAS study here.

Photo by CFPhotosin Photography on Unsplash

Singapore's Higher Education Ecosystem Driving AMR Innovations

NTU's LKCMedicine, a NTU-Imperial College London joint venture, exemplifies Singapore's higher ed prowess. Pablo Bifani, corresponding author and A*STAR principal investigator with NTU ties, leads AMR efforts. Collaborators Teck-Hui Teo (A*STAR) and Jeanette Teo (NUS) bolster multidisciplinary expertise. Singapore invests S$1B+ in AMR R&D via NRF, positioning universities as global leaders. LKCMedicine's phage labs integrate AI for mutant prediction, aligning with national Smart Nation goals.

This builds on prior NTU-A*STAR works: rifaximin-clarithromycin combos (2023) and anti-phage defenses (2020). Singapore's TB incidence (35/100k) and rising NTM cases underscore urgency; universities train clinician-scientists via PhD programs blending phage engineering and clinical trials.

Challenges in Phage Therapy: Beyond Morphotype Switching

Resistance isn't sole hurdle: phage purification for GMP, dosing (self-replicating but immunogenic), delivery to biofilms/lungs. Smooth strains form robust biofilms; rough invade tissues. Lysogeny risks horizontal gene transfer. Singapore addresses via phage banks (NUS Phage Directory) and compassionate use frameworks. Global trials (e.g., IPATH, Belgium) inform; NTU eyes zebrafish-to-human translation.

Real-World Impact: From Cystic Fibrosis to Global AMR

M. abscessus ravages cystic fibrosis lungs; phage therapy cleared infections in U.S. cases (rough strains). Singapore's 500+ annual NTM cases (MOH data) demand alternatives; 40% smooth prevalence heightens stakes. Broader AMR: WHO priority pathogen; phages could save 10M lives/year by 2050. NTU's work enables diagnostics tracking GPL mutations via PCR, guiding therapy.

Stakeholders: Patients gain hope; clinicians precision tools; policymakers evidence for funding. Economic: AMR costs Singapore S$1B/year; phages cheaper long-term.BioSpectrum Asia coverage details clinical relevance.

Future Directions: Cocktails, Engineering, and Trials

NTU proposes: Multi-phage libraries screening 1000+ isolates; CRISPR-edited phages sans lysogeny genes; phage-antibiotic synergies. Pre-clinical: Chronic mouse CF models. Clinical: Phase I safety in Singapore (HSA greenlit compassionate phages). Universities like NTU offer PhD/MSc in phage biotech; collaborations with pharma (Armata, PhageGuard).

Photo by TSquared Lab on Unsplash

• Short-term: Validate cocktails in mixed infections.
• Medium: Human pharmacokinetics.
• Long: Personalized phage via rapid sequencing.

Stakeholder Perspectives: Voices from Singapore Academia

Prof. Pablo Bifani (NTU/A*STAR): "This switching explains therapy failures; cocktails bridge the gap." Dr. Teck-Hui Teo (A*STAR): "Asian strain diversity demands region-specific phages." LKCMedicine students contribute via undergrad projects, fostering next-gen AMR fighters. Singapore's ecosystem—NRF grants, Biopolis—amplifies impact.

Actionable Insights for Researchers and Students

Aspiring microbiologists: Pursue NTU's MSc Microbiology; sequence local isolates for phage banks. Labs: Screen dual-morphotype cocktails routinely. Policymakers: Fund S$100M phage hub. Patients: Advocate phage access via SingHealth trials. Track via WHO GLASS; Singapore's NAPAR 2020-25 prioritizes alternatives.

This NTU-led advance exemplifies higher education's role in solving AMR, blending discovery with translation for healthier futures.